v3.26.1
Unaudited Condensed Consolidated Interim Statements of Changes in Stockholders’ Deficit - USD ($)
$ in Thousands
Preferred Stock
Common Stock
Common Stock
Previously Reported
Additional paid-in capital
Accumulated deficit
Accumulated Other Comprehensive Income (Loss)
Non-controlling interest
Total
Balance at Sep. 30, 2023 [1]   $ 25,544 $ (31,769) $ 32   $ (6,193)
Balance (in Shares) at Sep. 30, 2023 1,259,333            
Stock-based compensation   230   230
Issuance of Old Nukk common stock in exchange for a receivable from Brilliant [1]   1,802   1,802
Issuance of Old Nukk common stock in exchange for a receivable from Brilliant (in Shares)   47,533            
Issuance of Old Nukk common stock to settle accrued expenses and other current liabilities [1]   213   213
Issuance of Old Nukk common stock to settle accrued expenses and other current liabilities (in Shares)   5,629            
Issuance of common stock to settle accrued expenses and other current liabilities [1]   1,880   1,880
Issuance of common stock to settle accrued expenses and other current liabilities (in Shares)   361,532            
Issuance of stock purchase warrants   518   518
Issuance of common stock to settle loans payable – related parties [1]   271   271
Issuance of common stock to settle loans payable – related parties (in Shares)   8,767            
Issuance of common stock to settle due to affiliates [1]   2,727   2,727
Issuance of common stock to settle due to affiliates (in Shares)   94,710            
Issuance of common stock in connection with reverse recapitalization [1]   150   150
Issuance of common stock in connection with reverse recapitalization (in Shares)   321,495            
Foreign currency translation adjustments   (177)   (177)
Comprehensive income (loss) for the period   (8,519)   (8,519)
Balance at Sep. 30, 2024 [1]   33,335 (40,288) (145)   (7,098)
Balance (in Shares) at Sep. 30, 2024 2,098,999            
Rounding of post-split shares outstanding per transfer agent [1]     [1]
Rounding of post-split shares outstanding per transfer agent (in Shares) 57            
Stock-based compensation   6   6
Issuance of common stock as compensation for services [1]   1,364   1,364
Issuance of common stock as compensation for services (in Shares) 847,500            
Issuance of common stock in connection with Exit and Settlement Agreement [1]   325   325
Issuance of common stock in connection with Exit and Settlement Agreement (in Shares) 140,100            
Issuance of common stock as compensation to board of directors [1]   959   959
Issuance of common stock as compensation to board of directors (in Shares) 690,000            
Issuance of common stock to settle accrued expenses and other current liabilities [1]   760   760
Issuance of common stock to settle accrued expenses and other current liabilities (in Shares) 354,660            
Issuance of common stock to settle convertible notes payable [1]   771   771
Issuance of common stock to settle convertible notes payable (in Shares) 319,952            
Issuance of common stock in connection with private placement and embedded derivative, net of issuance costs [1]     [1]
Issuance of common stock in connection with private placement and embedded derivative, net of issuance costs (in Shares) 230,000            
Reclassification of stock purchase warrants from equity-classified to liability-classified   (238)   (238)
Issuance of common stock, net of issuance of costs [1]   478   478
Issuance of common stock, net of issuance of costs ( in Shares) 249,263            
Foreign currency translation adjustments   111   111
Comprehensive income (loss) for the period   (160,788)     (160,788)
Balance at Dec. 31, 2024 [2]   37,760 (201,076) (34) (163,350)
Balance (in Shares) at Dec. 31, 2024 39,444 [3] 4,930,531          
Issuance of common stock from exercise of pre-funded warrants [2]   3,056 3,056
Issuance of common stock from exercise of pre-funded warrants (in Shares) [3]   667            
Stock-based compensation   178 178
Foreign currency translation adjustments   (59) (59)
Comprehensive income (loss) for the period   102,958 102,958
Balance at Mar. 31, 2025 [2]   40,994 (98,118) (93) (57,217)
Balance (in Shares) at Mar. 31, 2025 [3]   40,111            
Balance at Dec. 31, 2024 [2]   37,760 (201,076) (34) (163,350)
Balance (in Shares) at Dec. 31, 2024 39,444 [3] 4,930,531          
Comprehensive income (loss) for the period               105,977
Balance at Jun. 30, 2025 [2]   41,932 (95,099) (216) (53,383)
Balance (in Shares) at Jun. 30, 2025 42,967 [3]            
Balance at Dec. 31, 2024 [2]   37,760 (201,076) (34) (163,350)
Balance (in Shares) at Dec. 31, 2024 39,444 [3] 4,930,531          
Issuance of common stock from exercise of warrants $ 1   31,918 31,919
Issuance of common stock from exercise of warrants (in Shares)   7,185,861            
Stock-based compensation $ 1   18,825 18,826
Stock-based compensation (in Shares)   3,370,000            
Issuance of common stock and warrants for services performed [1]   2,817 2,817
Issuance of common stock and warrants for services performed (in Shares)   310,000            
Issuance of common stock in relation to settlement agreement [1]   157 157
Issuance of common stock in relation to settlement agreement (in Shares)   12,500            
Issuance of common stock in relation to conversion of note [1]   1,792 1,792
Issuance of common stock in relation to conversion of note (in Shares)   503,455            
Issuance of common stock from exercise of options [1]   [1] [1]
Issuance of common stock from exercise of options (in Shares)   85,710            
Issuance of common stock in exchange for digital assets [1]   4,360 4,360
Issuance of common stock in exchange for digital assets (in Shares)   522,710            
Issuance of equity-classified warrants   7,080 7,080
Adjustments in relation to deconsolidation of subsidiary   213 213
Commitment to issue shares as penalty   300 300
Shares issued as commitment for ELOC agreement   1,250 1,250
Issuance of shares as collateral for investment [1]   [1] [1]
Issuance of shares as collateral for investment (in Shares)   2,000,000            
Issuance of shares for settlement of debt on related party [1]   509 509
Issuance of shares for settlement of debt on related party (in Shares)   105,000            
Capital contribution – SCII   882 6,108 6,990
Accretion of noncontrolling interests subject to possible redemption            
Accretion of Noncontrolling interests Subject to Possible Redemption       (4,913) (1,981) (6,894)
Foreign currency translation adjustments   (179) (179)
Comprehensive income (loss) for the period   78,549 82 78,631
Balance at Dec. 31, 2025 $ 2   102,737 (122,527) 4,209 (15,579)
Balance (in Shares) at Dec. 31, 2025 152,206 [3] 19,025,767          
Balance at Mar. 31, 2025 [2]   40,994 (98,118) (93) (57,217)
Balance (in Shares) at Mar. 31, 2025 [3]   40,111            
Issuance of common stock in relation to settlement agreement [2]   157 157
Issuance of common stock in relation to settlement agreement (in Shares) [3]   100            
Issuance of common stock in relation to conversion of note   [2]   781       781
Issuance of common stock in relation to conversion of note (in Shares) [3]   2,082            
Issuance of common stock from exercise of options [2]            
Issuance of common stock from exercise of options (in Shares) [3]   674            
Foreign currency translation adjustments           (123)   (123)
Comprehensive income (loss) for the period         3,019     3,019
Balance at Jun. 30, 2025 [2]   41,932 (95,099) (216) (53,383)
Balance (in Shares) at Jun. 30, 2025 42,967 [3]            
Balance at Dec. 31, 2025 $ 2   102,737 (122,527) 4,209 (15,579)
Balance (in Shares) at Dec. 31, 2025 152,206 [3] 19,025,767          
Issuance of common stock from exercise of warrants [2]   4,960 4,960
Issuance of common stock from exercise of warrants (in Shares) [3]   27,871            
Stock-based compensation [2]   1,907 1,907
Stock-based compensation (in Shares) [3]   3,800            
Issuance of common stock in relation to private placement [2]   [2] [2]
Issuance of common stock in relation to private placement (in Shares) [3]   19,512            
Issuance of preferred stock in relation to private placement  
Issuance of preferred stock in relation to private placement (in Shares) 200              
Issuance of common stock for purchase of subsidiaries $ 1   24,902 24,903
Issuance of common stock for purchase of subsidiaries (in Shares) [3]   52,963            
Issuance of common stock in relation to conversion of note [2]   3,153 3,153
Issuance of common stock in relation to conversion of note (in Shares) [3]   13,000            
Equity classified warrants issued as part of purchase of subsidiaries   45,646 45,646
Shares issued as penalty [2]   [2] [2]
Shares issued as penalty (in Shares) [3]   585            
Shares issued to settle commitment under ELOC agreement [2]   [2] [2]
Shares issued to settle commitment under ELOC agreement (in Shares) [3]   2,439            
Issuance of shares from ELOC exercises $ 1   3,529 3,530
Issuance of shares from ELOC exercises (in Shares) [3]   31,745            
Issuance of shares for settlement of debt on related party [2]   300 300
Issuance of shares for settlement of debt on related party (in Shares) [3]   1,600            
Subsidiary consolidation for the first time   (139) 1,739 1,600
Accretion of noncontrolling interests subject to possible redemption   (1,275) (514) (1,789)
Foreign currency translation adjustments   115 128 243
Comprehensive income (loss) for the period   (27,147) 796 (26,351)
Balance at Mar. 31, 2026 $ 4   185,859 (149,674) (24) 6,358 42,523
Balance (in Shares) at Mar. 31, 2026 200 305,721 [3]            
Balance at Dec. 31, 2025 $ 2   102,737 (122,527) 4,209 (15,579)
Balance (in Shares) at Dec. 31, 2025 152,206 [3] 19,025,767          
Issuance of common stock in relation to conversion of note        
Issuance of common stock from exercise of options      
Shares issued to settle commitment under ELOC agreement (in Shares)               14,800
Foreign currency translation adjustments      
Comprehensive income (loss) for the period     $ (107,780)
Balance at Jun. 30, 2026 $ 10   207,104 (232,162) (276) 5,665 (19,659)
Balance (in Shares) at Jun. 30, 2026 200 758,660 [3]            
Balance at Mar. 31, 2026 $ 4   185,859 (149,674) (24) 6,358 42,523
Balance (in Shares) at Mar. 31, 2026 200 305,721 [3]            
Issuance of common stock from exercise of warrants $ 3   12,795 12,798
Issuance of common stock from exercise of warrants (in Shares) 211,544 [3]            
Issuance of common stock in relation to conversion of note   2,139 2,139
Issuance of common stock in relation to conversion of note (in Shares) [3]   33,395            
Issuance of shares from ELOC exercises $ 2   4,541 4,543
Issuance of shares from ELOC exercises (in Shares) [3]   160,000            
Issuance of common stock in connection with the VisionWave share exchange $ 1   2,353 2,354
Issuance of common stock in connection with the VisionWave share exchange (in Shares) [3]   48,000            
Transaction with non-controlling interests and deconsolidation of subsidiary   358 (1,140) (782)
Accretion of noncontrolling interests subject to possible redemption   (941) (380) (1,321)
Foreign currency translation adjustments   (252) (231) (483)
Comprehensive income (loss) for the period         (82,488)   1,058 (81,430)
Balance at Jun. 30, 2026 $ 10   $ 207,104 $ (232,162) $ (276) $ 5,665 $ (19,659)
Balance (in Shares) at Jun. 30, 2026 200 758,660 [3]            
[1] Less than $1 thousand.
[2] Less than $1 thousand.
[3] Share amounts have been retroactively adjusted to reflect the 1-for-125 Reverse Stock Split (see Note 1).